Biography

Director, GI & Bariatric Research, HonorHealth Research Institute

Medical Director, HonorHealth Bariatric Center

Clinical Associate Professor of Surgery, University of Arizona College of Medicine – Phoenix

 

James M. Swain, MD, FACS, FASMBS, is a nationally recognized bariatric and minimally invasive surgeon who serves as Medical Director of the HonorHealth Bariatric Center and Director of GI & Bariatric Research at the HonorHealth Research Institute. With more than 25 years of experience in obesity and metabolic disease treatment, he specializes in advanced bariatric surgery, innovative endoscopic weight-loss therapies, and metabolic research.

 

Dr. Swain earned his medical degree from the University of Kansas School of Medicine and completed his general surgery residency at Mayo Clinic Arizona. He subsequently completed a fellowship in minimally invasive surgery at Mayo Clinic in Jacksonville, Florida. Prior to joining HonorHealth, he served as Director of Bariatric Surgery at both Mayo Clinic Arizona and Mayo Clinic Rochester.

 

A leader in obesity-related innovation, Dr. Swain has served as Principal Investigator for more than 50 clinical trials focused on obesity, metabolic disease, gastroesophageal reflux disease (GERD), metabolic surgery, endoscopic weight-loss procedures, anti-obesity devices, and emerging genetic obesity therapies. He currently leads multiple prospective, randomized FDA-regulated clinical trials.

 

Dr. Swain has presented extensively at national and international scientific meetings and has authored more than 80 peer-reviewed publications. He has also contributed to leading surgical textbooks and serves on multiple editorial boards. In addition to his clinical and research leadership roles, he is a Clinical Associate Professor of Surgery at the University of Arizona College of Medicine – Phoenix, where he contributes to the education and mentorship of future surgeons and physician-scientists.

Research Interests & Focus

Dr. Swain’s current research focuses on advancing next‑generation therapies for obesity and metabolic disease. His work centers on innovative endoscopic and minimally invasive technologies, device‑based solutions for obesity and GERD, and the evaluation of new pharmacologic treatments and combination‑therapy approaches. He is actively leading clinical trials designed to improve long‑term weight loss, durability, safety, and metabolic outcomes across a broad range of obesity treatments.

Important Notice: Email is not monitored for urgent or time-sensitive matters. Please do not use email to request medical advice, report symptoms, or communicate about emergencies. If you have an urgent need, please call our toll-free number at 833-354-6667.